Calidi Biotherapeutics annual shareholders’ equity
2021
2022
2023
2024
2025
Calidi Biotherapeutics Shareholders’ Equity Growth & History (CLDI)
Calidi Biotherapeutics's shareholders’ equity was $3.8M for fiscal 2025.
View full Calidi Biotherapeutics company overviewCalidi Biotherapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.8M | $2.2M | +145.05% |
| 2024 | 2024-12-31 | $1.5M | $9.8M | — |
| 2023 | 2023-12-31 | −$8.2M | $42.2M | — |
| 2022 | 2022-12-31 | −$50.4M | −$18.8M | — |
| 2021 | 2021-12-31 | −$31.6M | — | — |
Calidi Biotherapeutics quarterly shareholders’ equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.1M | $1.4M | +77.61% |
| Q1 2026 | 2026-03-31 | $4.9M | −$2.0M | −28.90% |
| Q4 2025 | 2025-12-31 | $3.8M | $2.2M | +145.05% |
| Q3 2025 | 2025-09-30 | $6.9M | $16.7M | — |
| Q2 2025 | 2025-06-30 | $1.8M | $13.5M | — |
| Q1 2025 | 2025-03-31 | $6.9M | $21.5M | — |
| Q4 2024 | 2024-12-31 | $1.5M | $9.8M | — |
| Q3 2024 | 2024-09-30 | −$9.8M | −$8.7M | — |
| Q2 2024 | 2024-06-30 | −$11.8M | $52.0M | — |
| Q1 2024 | 2024-03-31 | −$14.6M | $40.5M | — |
| Q4 2023 | 2023-12-31 | −$8.2M | $42.2M | — |
| Q3 2023 | 2023-09-30 | −$1.1M | $42.8M | — |
| Q2 2023 | 2023-06-30 | −$63.7M | −$24.1M | — |
| Q1 2023 | 2023-03-31 | −$55.1M | −$41.9M | — |
| Q4 2022 | 2022-12-31 | −$50.4M | −$18.8M | — |
| Q3 2022 | 2022-09-30 | −$43.9M | −$25.0M | — |
| Q2 2022 | 2022-06-30 | −$39.6M | — | — |
| Q1 2022 | 2022-03-31 | −$13.2M | — | — |
| Q4 2021 | 2021-12-31 | −$31.6M | — | — |
| Q3 2021 | 2021-09-30 | −$19.0M | — | — |
Calidi Biotherapeutics shareholders’ equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Calidi Biotherapeutics's shareholders’ equity increased from −$31.6M to $3.8M, a change of $35.4M. The latest reported quarter, Q2 2026, shows $3.1M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Calidi Biotherapeutics source filings ↗